News | July 09, 2021
Pfizer and BioNTech expects third dose clinical studies of COVID-19 vaccine in August
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Subscribe To Our Newsletter & Stay Updated
